<DOC>
	<DOCNO>NCT00986570</DOCNO>
	<brief_summary>The purpose study determinate whether Xeomin® ( Botulinum toxin Type A ) safe , effective tolerable woman age 30 50 year old treatment mild , moderate severe expression line ( wrinkle ) upper third face . The main outcome change appearance wrinkle two week ( visit 3 ) product application compare baseline assessment .</brief_summary>
	<brief_title>Clinical Trial Assess Efficacy , Safety Tolerability Botulinum Toxin A ( Xeomin® ) Treatment Expression Wrinkles Upper Third Face</brief_title>
	<detailed_description>Ageing dynamic unchangeable process involve individual affect several organic system . This process express multiple symptom sign , wrinkle flaccidity common visible one . In developed emerge country , interest skin ageing , great extent , result progressive increase absolute number proportion people experience age process last century . The psychosocial , well physiological effect skin age raise huge demand well understanding process , particular , effective intervention . The use botulinum toxin type-A ( BTX/A ) aesthetic indication emerge result clinical observation patient treat facial different dystonia present additional improvement expression line . The expression line easily note upper third face , surgical treatment fully invasive show lesser noticeable result . The upper third face target BTX/A treatment report several scientific literature article well succeed .</detailed_description>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Women age 30 50 year old , inclusive . Mild , moderate severe expression wrinkle . Patients understood sign Informed Consent Form . Subjects treat botulinum toxin upper third face within previous 6month period ; Former implantation permanent material surgery ( scar ) . Use anticoagulant agent 7 day prior investigational product application ; Concomitant use aminoglycosides drug may impair neuromuscular transmission ; Coagulopathies local inflammation/ infection application site . Diseases impact neuromuscular function , : myasthenia gravis , Eaton Lambert Syndrome ; Pregnancy breast feeding , woman potential become pregnant agree use effective contraception method ( Pearl Index &lt; 1 % ) ; Allergy know sensitivity component investigational drug ; Subjects enrol clinical trial last 12month period prior present study , per Resolution 251/97 ; Subjects disagree study procedure , sign Informed Consent Form commit participate trial .</criteria>
	<gender>Female</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Botulinum Toxin A</keyword>
	<keyword>Wrinkles</keyword>
</DOC>